LEADER 05478nam 2200649Ia 450 001 9910784648603321 005 20200520144314.0 010 $a1-281-00533-9 010 $a9786611005337 010 $a0-08-049251-7 035 $a(CKB)1000000000364187 035 $a(EBL)294538 035 $a(OCoLC)469589848 035 $a(SSID)ssj0000111864 035 $a(PQKBManifestationID)11124919 035 $a(PQKBTitleCode)TC0000111864 035 $a(PQKBWorkID)10085624 035 $a(PQKB)11005513 035 $a(Au-PeEL)EBL294538 035 $a(CaPaEBR)ebr10186063 035 $a(CaONFJC)MIL100533 035 $a(MiAaPQ)EBC294538 035 $a(PPN)18257332X 035 $a(EXLCZ)991000000000364187 100 $a20050202d2005 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aBioindustry ethics$b[electronic resource] /$fDavid L. Finegold ... [et al.] 210 $aAmsterdam ;$aBoston $cElsevier Academic Press$dc2005 215 $a1 online resource (384 p.) 300 $aIncludes index. 311 $a0-12-369370-5 327 $aBIOINDUSTRY ETHICS; BIOINDUSTRY ETHICS; Contents; Research Team; Preface; Acknowledgments; Introduction; ETHICAL ISSUES CONFRONTING BIOSCIENCE COMPANIES; WHY SHOULD BIOSCIENCE FIRMS CARE ABOUT ETHICS?; ETHICISTS AND THE BIOSCIENCE INDUSTRY; A NEW APPROACH: BIOSCIENCE BUSINESS ETHICS; STRUCTURE OF THE BOOK; Merck: Staying the Course; INTRODUCTION; FOCUSING ON PATIENTS AND THE LONG TERM; ETHICS RESOURCE CENTERS; INTERNAL ETHICAL PRACTICES; ASSESSING THE IMPACT; BENEFITS OF AN ETHICAL APPROACH; ETHICAL ISSUES; DRUG PRICING, ACCESS, AND INTELLECTUAL PROPERTY 327 $aCLINICAL TRIALS AND PUBLICATION OF RESULTSWHAT DRUGS TO DEVELOP; CHALLENGES FOR THE FUTURE; Genzyme: Putting Patients First; INTRODUCTION; PUTTING THE PATIENT FIRST: GENZYMEI?S APPROACH TO ETHICAL ISSUES; ETHICAL ISSUES; ETHICAL MECHANISMS; SUSTAINING THE GENZYME CULTURE; CONCLUSION; Millennium pharmaceuticals, Inc.: Creating and Sustaining Corporate Values; INTRODUCTION; MILLENNIUM PHARMACEUTICALS INC.; INSTITUTIONALIZING CORE VALUES AND ETHICS; ETHICS EDUCATION PROGRAMS; IMPACT OF INSTITUTIONALIZATION OF VALUES AND ETHICS; PRESERVING A FOCUS ON CORE VALUES; THE FUTURE 327 $aMaxim Pharmaceuticals (A): Internal and External DialoguesAN UNUSUAL BIOTECH LEADER; THE IMPACT OF BUSINESS ETHICS IN THE BIOSCIENCE INDUSTRY; COMPANY HISTORY; EMBEDDING CORE VALUES; MECHANISMS FOR EMBEDDING CORE VALUES; BUILDING A SUCCESSFUL GLOBAL BOARD; ANNUAL STRATEGIC RETREAT; DEALING WITH ETHICAL ISSUES; MAXIM PHARMACEUTICALS (B); Diversa Inc.: Ethical Issues in Bioprospecting Partnerships; FROM BIOPIRACY TO BIOPROSPECTING; THE COMPANY; THE CONTEXT FOR BIOPROSPECTING PARTNERSHIPS; DIVERSAI?S BIODIVERSITY COLLABORATIONS; PROCESS FOR ESTABLISHING AND IMPLEMENTING COLLABORATIVE AGREEMENTS 327 $aETHICAL DECISION MAKINGTOWARD THE FUTURE; DIVERSA INC. (B); DIVERSA INC. (C); DIVERSA INC. (D); Pipeline Biotech A/S: Competing Regulatory Regimes for Laboratory Animal Experiments; INTRODUCTION; COMPANY HISTORY; BUSINESS MODEL AND ETHICAL APPROACH; EMPOWERING THE WORKFORCE; ETHICAL ISSUES AT PIPELINE; CONCLUSION; TGN Biotech: A Start-Up with Ethical Roots; WHAT NOW?; TGN BIOTECH; TGNI?S MARKET; SEMENESISTM; WHY PIGS AND WHY SEMEN?; THE ETHICAL ISSUES; MECHANISMS FOR A TRANSPARENT PROCESS; FUTURE POSSIBILITIES; WHAT NEXT?; Interleukin Genetics and Alticor: An Unlikely Partnership; INTRODUCTION 327 $aCOMPANY ORIGINSEXPLORING THE ETHICS OF GENETIC TESTING; FAILED EFFORTS TO BUILD A PERSONALIZED MEDICINE BUSINESS; PUTTING ETHICS EXPERTS IN CHARGE; APPROACH TO ETHICAL ISSUES; PROPOSED ALTICOR DEAL; INTERLEUKIN GENETICS AND ALTICOR: AN UNUSUAL PARTNERSHIP; CREATING AN ETHICAL APPROACH TO NUTRIGENOMICS; Sciona Ltd.: A Pioneer in Nutrigenomics: The Path to Consumer Acceptance; INTRODUCTION; BACKGROUND; PRODUCT LAUNCH; ETHICAL CONSIDERATIONS; THE CASE FOR ETHICS; APPLICATION TO THE HUMAN GENETICS COMMISSION; PUBLIC OPPOSITION; RESULTS; THE HGC RECOMMENDATIONS; TOWARD THE FUTURE 327 $aAffymetrix, Inc.: Using Corporate Ethics Advice 330 $aThis book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies. The application of genetic/genomic technologies raises a whole spectrum of ethical questions affecting global health that must be addressed. Topics covered in this comprehensive survey include considerations for bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics, as well as how to improve stakeholder relations, design ethical clinical trials, avoid conflicts of interest, and establish ethics advisory boards. The expert authors represen 606 $aBiotechnology industries$xMoral and ethical aspects$vCase studies 606 $aPharmaceutical industry$xMoral and ethical aspects$vCase studies 606 $aBusiness ethics$xMoral and ethical aspects$vCase studies 615 0$aBiotechnology industries$xMoral and ethical aspects 615 0$aPharmaceutical industry$xMoral and ethical aspects 615 0$aBusiness ethics$xMoral and ethical aspects 676 $a174/.96606 701 $aFinegold$b David$0728221 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910784648603321 996 $aBioindustry ethics$93843626 997 $aUNINA